GAMMA Investing LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

GAMMA Investing LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 41,658.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,540 shares of the company's stock after acquiring an additional 93,316 shares during the quarter. GAMMA Investing LLC owned 0.31% of Medpace worth $28,501,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MEDP. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares in the last quarter. HBK Sorce Advisory LLC raised its position in Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the period. Proficio Capital Partners LLC grew its position in shares of Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. grew its position in shares of Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird lowered their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Finally, Mizuho dropped their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $349.30.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This represents a 36.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.30% of the company's stock.

Medpace Trading Up 1.0%

Shares of MEDP traded up $2.92 during midday trading on Friday, hitting $296.50. 421,400 shares of the company's stock traded hands, compared to its average volume of 358,033. The stock has a market capitalization of $8.52 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The firm's fifty day moving average is $298.09 and its 200-day moving average is $324.07.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. During the same quarter in the previous year, the firm earned $3.20 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.